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ABSTRACT

ARTICLE HISTORY

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) pan
demic during the fall of 2019 led to the rapid development of vaccines aimed at curbing viral infection,
spread, and its potential eradication. A recent trend is an overall increase in vaccine hesitancy, leading to
the World Health Organization citing this as a problem which needs to be addressed. With the develop
ment and approval of vaccines for COVID-19, this trend has quickened, leading to potential negative
ramifications in the ability controlling COVID-19 spread. Here we describe reported examples in overall
vaccine hesitancy prior to the emergence of COVID-19, as well as summarizing recent reports on vaccine
hesitancy related to COVID-19 vaccines. Gaining a better understanding of the reasons individuals have, as
well as potential methods for decreasing hesitancy in the future, will hopefully lead to a greater percen
tage of vaccinated individuals and aid in ending the current pandemic.
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Introduction
The emergence of the severe acute respiratory syndrome cor
onavirus 2 (SARS-CoV-2; COVID-19) pandemic during the
fall of 2019 led to the rapid spread of COVID-19 infections
worldwide. The resulting numbers of severe cases and hospi
talizations placed massive strain on local, regional, and world
wide health systems. Almost immediately, world leaders in
Government and the Health Care Industry called for the
rapid development, testing, and implementation of COVID19 vaccines aimed at curbing viral infection, spread, and poten
tially its eventual eradication. Although the vaccines have been
effective in decreasing infection rates of early strains, along
with the morbidity and mortality of more recent variants
such as Omicron, they have been met with high levels of
hesitancy.
Current COVID-19 vaccine statistics
As of March 14th, 2022, approximately 63.8% of the world
population has received at least one dose of a COVID-19
vaccine.1 This equates to approximately 10.94 billion doses.
A general trend is that urban and suburban counties have
higher vaccinations than rural counties. The percentages of
fully vaccinated individuals are higher based on age, with
a higher percentage of older individuals being fully vaccinated
(including having received a booster) than younger people.
Additionally, the number of vaccine doses administered to
upper middle and high income individuals is vastly higher
than those in lower-middle and low income brackets.1 This
data follows the trends from early surveys regarding vaccine
hesitancy.
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In terms of efficacy of the COVID-19 vaccines, the United
States Centers for Disease Control and Prevention reports
a vaccine efficacy against symptomatic infection of 93.5% against
Delta variant, and a 67% vaccine effectiveness against sympto
matic infection for the Omicron variant when compared to
unvaccinated individuals. In terms of hospitalizations, full vacci
nation (three doses of mRNA-based vaccine) was 94% effective vs.
Delta and 90% effective vs Omicron when compared to nonvaccinated individuals.2 As of January 1st, 2022, the United
States death rate per 100,000 population of fully vaccinated indi
viduals (including boosters) was .45 while the unvaccinated death
rate was 12.06.3 COVID-19 vaccine side effects have also been
reported, with very low rates. Anaphylaxis, a severe type of allergic
reaction that can occur after any type of vaccination, has occurred
in approximately five people per million vaccinated in the United
States.4 Thrombosis with thrombocytopenia syndrome (TTS)
after Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19
Vaccination was found in 59 cases in more than 18.4 million
doses, and only 4 cases have been reported in the 535 million
doses of mRNA COVID-19 vaccines as of 3 March 2022.4 305
preliminary reports of Guillain-Barré Syndrome have been
reported from the 18.4 million J&J/Janssen COVID-19 vaccina
tion, largely in men over age 50 years and older. Myocarditis,
inflammation of the heart muscle, and pericarditis, inflammation
of the outer lining of the heart, after COVID-19 vaccination, as of
3 March 2022, have been reported in 2,282 individuals, with most
cases having been reported after receiving mRNA based vaccines,
and most commonly in males under 30 years of age.4 Finally, out
of the 555 million doses, 12,989 preliminary reports of death were
reported among people who received a COVID-19 vaccine
(.0023%); however these are not specifically tied to the vaccine
administration.4
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Vaccine hesitancy
Despite the success of vaccines preventing and reducing
transmission of a number of pathogenic diseases, such as
smallpox and polio,5–9 hesitancy and resistance toward
vaccination is not a new phenomenon.10–18 Vaccine hesi
tancy is described as a “delay in acceptance or refusal of
vaccines despite availability of vaccination services”.19
A multitude of factors have been identified as contributing
to the hesitancy of vaccine uptake, including contextual
influences, individual and group influences, as well as vac
cine/vaccination-specific issues.19 Due to this complexity,
recognizing and addressing vaccine hesitancy are not
always straightforward, as the decision of a person to vac
cinate themselves or their child is multifactorial.15,19,20
Despite extensive data documenting vaccine safety,21
recent studies demonstrate that concerns over serious side
effects and overall vaccine safety are major factors influen
cing the uptake of both routine vaccinations and annual
influenza vaccinations.13,22,23 In addition, the fear of nee
dles and/or blood has also been identified as a factor for
refusing a vaccine.23,24 Safety concerns have also been iden
tified due to individuals potentially having an allergic reac
tion to a vaccine component or prior negative experiences
with respect to vaccinations.23 Vaccine schedules, costs, and
reliability also factor into the decision regarding vaccine
uptake.19
Another common influence on individuals’ decisions
regarding vaccines was based upon religious thought. While
major religious leaders typically support vaccines in principal,
another factor influencing vaccine hesitancy is based on perso
nal religious affiliations, with religious and ethical based objec
tions to vaccination dating as far back as the late 1700s.25
Religious-based vaccine hesitancy has been a noted factor in
the outbreak of vaccine-preventable diseases affecting religious
communities and settings.25,26 A recent study found that US
clergy from multiple religions have complex attitudes toward
vaccines and the promotion of vaccines within their
congregations.26 Concerns over the use of blood components,
pharmaceutical excipients of porcine or bovine origin, and cellculture media or media constituents of fetal origin are all
factors associated with religion-based hesitancy.25,26
Other contextual influences also must be considered in
terms of vaccine hesitancy, including historical, sociocultural, environmental, health system/institutional, economic,
and political factors.19 A common theme of philosophical
exemption is rooted in the basis of personal belief. These beliefs
are often shaped by the media, government, political leaders
and policies, geographical barriers, as well as the perception of
the pharmaceutical industry. Philosophical resistance to vac
cines and vaccinations has been reported since the first vaccine
mandate for smallpox in the 1850s and can reasonably be
considered the beginning of the anti-vaccination
movement.12 One of the main reasons for such a movement
was due to the mandate requiring the vaccination of children
up to fourteen years old. If parents had not abided by such
mandates, they were subject to fines and imprisonment, which
spurred social unrest.27

Hesitancy toward vaccination is profoundly concerning as
the emergence of vaccine resistance and antivaccination move
ments has accompanied the increase in incidence of some
communicable diseases.24 Measles, for example, was once con
sidered eradicated in the US due to vaccination efforts that
became available during the 1960s.28 However, in 2011,
a significant increase in cases was reported and was determined
to be mainly due to unvaccinated individuals who traveled
outside of the US, contracting it while abroad.12 In addition,
measles cases increased considerably again in January 2019 with
over 700 cases having been reported, with roughly 70% of those
cases in unvaccinated individuals.29 Examples of vaccine pre
ventable disease outbreaks such as these raises concerns for the
safety of public health at large, both in the US and globally.
It is critical to note that being vaccine hesitant and being
against vaccinations in general are not the same. Determinants
for vaccine refusal and hesitancy include modifying factors,
such as age, gender, ethnicity, and other demographic vari
ables, along with individual beliefs such as perceived suscept
ibility to and severity of the disease, along with the perceived
benefits and barriers of vaccination all playing a prominent
role.30,31 Thus, it is imperative to continuously reexamine
motives for vaccine hesitancy, especially as new vaccines and
vaccine technologies are introduced, in an attempt to reduce
vaccine hesitancy for the health of our communities. In this
narrative review, our aim was to examine and describe factors
influencing COVID-19 vaccine hesitancy, mainly in the con
text of the United States, with a purpose of providing
a summary of information on factors driving COVID-19 vac
cine refusal.

Materials and methods
Search strategy
Literature searches were conducted between October 13th,
2021 and November 15th, 2021 to have a more comprehensive
understanding of the focused research topic. Published papers
in PubMed/Medline that aimed at evaluating COVID-19 vac
cine hesitancy and vaccine acceptance were eligible for inclu
sion. Only studies in English language that met the inclusion
criteria were considered in this review. The inclusion criteria
were: 1) peer-reviewed published articles indexed in
PubMed; 2) the major aim of the study was to evaluate
COVID-19 vaccine acceptance or hesitancy; and 3) the pub
lication language was English. Exclusion criteria were 1)
unpublished manuscripts; 2) the article did not aim to evaluate
COVID-19 vaccine acceptance/hesitancy; and 3) the publica
tion language was not English. Searches were conducted using
the following terms: (COVID-19 * vaccine [Title/Abstract])
OR (COVID-19 * vaccine * hesitancy [Title/Abstract]) OR
(COVID-19 * vaccine * acceptance [Title/Abstract]) OR
(Vaccine * hesitancy [Title/Abstract]). Original studies and
reviews focusing on vaccine acceptance, willingness, hesitancy,
or intention regarding the COVID-19 vaccine were examined
independently by all authors (K.P., K.G., and B.A.C.), followed
by a summarizing of the main points from each publication
and providing a collective narrative of conclusions.
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Hesitancy toward COVID-19 vaccines
Demographic variance
The development of vaccines aimed at preventing COVID-19
infection began with numerous announcements of clinical trial
data in November 2020, with federal and regulatory approvals
in early December of 2020. In the United States, Operation
Warp Speed aimed at delivering more than 300 million doses
of COVID-19 vaccines by January 2021. Numerous studies
began to examine the acceptance of the novel vaccines in
order to determine the likelihood of individuals to become
vaccinated.32–43 Generally, results show that from 50–76% of
those surveyed would likely become vaccinated, with approxi
mately 15–30% unsure, and between 7 and 20% reporting they
would not become vaccinated.33,35,41–43 There were numerous
demographic factors which seemed to play a role in the accep
tance or hesitancy toward vaccination. The older a person is,
the more likely they are to uptake the COVID-19
vaccine.33,40,41 In addition, lower levels of education and/or
income were associated with higher rates of hesitancy.35,40,41
While higher levels of education are reported to decrease
vaccine hesitancy, a study surveying medical students found
that 23% were unwilling to take the COVID-19 vaccine imme
diately upon FDA approval; however, 53% of those surveyed
did indicate they would take part in a COVID-19 vaccine
trial.37 Ethnicity and race were also listed as a contributing
factor, with vaccine hesitancy higher among Blacks and
Hispanics.33,35,36,38,39,41 Additional demographic factors that
have been reported to influence COVID-19 vaccine hesitancy
include gender, perceived health status and comorbidities,
religion, political affiliation, rural vs urban dwelling, and hav
ing children at home.32–43
It is important to note that the hesitancy toward vaccination
is very much dependent upon several unique elements, includ
ing spatial-temporal factors, demographic groups and sub
groups, as well as in a vaccine-specific context. A recent study
investigating the role of health beliefs and prior vaccine hesi
tancy in US mothers’ intentions to vaccinate against COVID19 found that a mother’s previous attitudes toward vaccina
tions did not fully capture their willingness to accept the
COVID-19 vaccine or the perception of COVID-19 threat.43
A similar study conducted in Italy found that parents of chil
dren with high average vaccination rates had a vaccine accep
tance rate of just above 26%.42 These studies highlight the
importance of investigating and understanding the variations
that likely exist, even across similar populations in regards to
vaccine hesitancy now, and in the future.
COVID-19 vaccine safety and efficacy
By far one of the most common reasons among vaccinehesitant individuals is the perceived safety of the
vaccines.37,44,45 COVID-19 vaccines were the fastest vaccines
ever to be developed, and with this comes the connotation of
rushed vaccine development and trials, which has led many
individuals to become skeptical of the safety of the vaccine. In
addition, the novelty of the mRNA-based technology for many
of the COVID-19 vaccines has increased these concerns.44–47
A study by Pogue et al. (2020) found that as the amount of time
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the COVID-19 vaccines spent in clinical trials increased, the
higher likelihood individuals would uptake the vaccine, with
the same holding true when asked about their willingness to
vaccinate their children.44 Increased testing and decreased side
effects were also associated with an increased likelihood to
vaccinate. General vaccine avoidance45along with general
fears of injections can explain only a fraction of individuals
not uptaking a COVID-19 vaccine.46 Furthermore, the efficacy
and length of immunity were also stated to have an influence
on vaccine hesitancy, with increases in both the efficacy and
immunity (as indicated by the need for boosters) ameliorated
some of the fears or hesitancy associated with the vaccine.44
Several of these studies have also found that the risk of side
effects affects the rate of vaccination for COVID-19. While the
Centers for Disease Control and the US Food and Drug
Administration continuously monitor the safety of the
COVID-19 vaccines, the potential of unknown risk(s) sur
rounding novel vaccines, especially when considering a novel
technology such as mRNA based vaccines, are strong determi
nants toward vaccine hesitancy. Furthermore, the reporting of
side effects with differential incidence rates among age groups
(such as a higher incidence of TTS and pericarditis in younger
individuals,4 poses the need for further discussion on the riskbenefit balance of the vaccine.
Government and health official mistrust
As reported by Coustasse et al. (2021),33 many individuals are
skeptical about the information provided by the government
and health organizations regarding COVID-19 and the new
vaccines. Mistrust in the development of vaccines, as well as
rates of misinformation have led to an increase in vaccine
hesitancy among the general public.37 Race and ethnicity
have been reported to play a fairly significant role in the
COVID-19 vaccine hesitancy due to mistrust in the health
system in general.36,38,39,48,49 According to Willis et al.49
“Distrust of the medical establishment by Black/African
Americans is often traced back to the Tuskegee syphilis
study, but the distrust is deeply rooted beyond a single incident
and is predicated on centuries of racist exploitation by medical
researchers and doctors. Racism within the medical establish
ment is ongoing, and Black/African Americans do not need an
extensive knowledge of the history of medical racism to inform
their view of vaccines when many only need to consider recent
experiences.” In addition, it is reported that misinformation
and information disputes among higher officials also lead to
a higher sense of mistrust among Blacks toward the healthcare
system.39 Additionally, combining the exploitation and prior
fears, vaccine mistrust seems far more prominent than vaccine
hesitancy among the black population.
Decreasing COVID-19 vaccine hesitancy
While its likely most individuals think of COVID-19 as a global
problem, a large number remain hesitant toward vaccines
against it. The development of efficacious and safe vaccines is
an enormous challenge and doing so quickly amid a pandemic
only adds to the issue. Hesitancy toward these vaccines adds
unique challenges that must be overcome. It is critical for
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health care professionals to provide consistent and accurate
messaging to individuals regarding the need and safety of the
COVID-19 vaccines.33 Additionally, governmental and health
care officials must provide transparent, steady and dependable
information, especially regarding the severity of the pandemic.
In regard to vaccine safety, it is important to educate indivi
duals on the function and benefits of vaccines. To do so it is
important that governments and health care officials be unified
in their message and promotion of the vaccine. Additionally, as
it has shown that rural and low-income areas have higher levels
of hesitancy, local leaders including religious leaders should
promote vaccinations. Furthermore, specific efforts must be
made toward racial and ethnic populations to ensure that
individuals in highly hesitant groups have access to and trust
the information regarding vaccination. Significance must be
placed on the overall global, social and community good of
vaccination against COVID-19 and the potential deleterious
outcomes of remaining unvaccinated.

Conclusions
Vaccines have the potential to prevent disease and death from
a number of viruses, including COVID-19. The hesitancy
shown toward the COVID-19 vaccines is not a new concept,
with a vast and varying number of reasons, and appropriate
measures need to be taken to minimize it. The emergence of
the highly transmissible variants, including Omicron, has led
to an increased number of breakthrough cases among vacci
nated individuals. Thus, it is important to continue to investi
gate individuals’ reasons for COVID-19 vaccine hesitancy and
find ways to promote vaccine uptake. While the vaccinations
may not fully prevent the disease, a lessening of the severity, as
well as decreases in the rates of hospitalizations and deaths in
fully vaccinated (including boosters) individuals has been
shown.2,3,50,51 As the COVID-19 pandemic continues to place
a stranglehold on health care systems, as well as local and
global economies, it is crucial to understand the reasons for
hesitancy in becoming vaccinated in order to provide critical
information and increase vaccination rates worldwide.
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